Cash and cash equivalents $732 $2,088
Other current assets 24 38
Total current assets 756 2,126
Property and other assets 228 270
Total assets $984 $2,396
Liabilities and stockholders'
Current liabilities $683 $193
Stockholders' equity (deficit) 301 2,203
Total liabilities and stockholders' equity $984 $2,396
Shares Outstanding 712,835 711,168
About GeoVax Labs, Inc.
GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.
GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines:
-- Protected 22 of 23 (96%) non-human primates for over 3 1/2 years post-
infection with an AIDS causing virus - 5 of 6 non-vaccinates controls
died of AIDS
-- Are manufactured and tested under GMP/GLP - EMEA (EU) and FDA
-- Satisfactorily completed early Phase 1 human clinical trial for DNA
-- Are currently in 2 ongoing human trials started in 2006 with positive
immune responses reported in the majority of vaccine recipients as well
as good vaccine safety
-- Began 2 additional human trials in June 2007 with a large Phase 2 trial
in planning for 2008
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved